UTILIZATION OF RECOMBINANT INFLUENZA VIRUSES AND MODIFIED VACCINIA ANKARA VIRUS (MVA) WITH GENES THAT ENCODE FOR THE TOXOPLASMA GONDII SAG1 AND SAG2 SURFACE PROTEINS, AS VACCINES AGAINST TOXOPLASMOSIS
Ricardo Tostes GAZZINELLI,Rafael Polidoro Alves BARBOSA,Braulia Costa CAETANO,Alexandre de Magalhaes Vieira MACHADO,Oscar BRUNA-ROMERO,Flavio Fonseca GUIMARAES,Erica Araujo MENDES
申请号：
US15907672
公开号：
US20180271965A1
申请日:
2018.02.28
申请国别(地区):
US
年份:
2018
代理人:
摘要：
The present invention concerns to recombinant influenza viruses and modified Vaccinia Ankara viruses (MVA), and to a process for construction of recombinant influenza viruses and modified vaccinia Ankara viruses (MVA) with genes that encode for the T. gondii parasite SAGI (MVA) and SAG2 (MVA and influenza) proteins, by means of a homologous recombination technique between two transfer vectors (for construction of MVA virus) and reverse genetics (for construction of influenza virus). Additionally, the present invention describes a vaccine composition using recombinant influenza viruses and modified vaccinia Ankara viruses (MVA), or recombinant adenoviruses and modified vaccinia Ankara viruses (MVA), for immunization against infections caused by the T. gondii parasite.
